BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the appointment of current President, John F. Thero, as President and Chief Executive Officer of the company, effective January 1, 2014. Mr. Thero will also be appointed to the Board of Directors, effective January 1, 2014. These appointments follow communication to the Board of Directors by Joseph S. Zakrzewksi of his intention to retire as Chief Executive Officer and Chairman of the Board of Directors of Amarin. In connection with Mr. Zakrzewski's retirement, Lars Ekman, MD, PhD, who currently serves as Lead Independent Director, will become Chairman of the Board, effective January 1, 2014. Mr. Zakrzewski will remain on the Board of Directors of Amarin. "It is with great pleasure and confidence that we appoint John Thero as President and Chief Executive Officer of Amarin. John has been a key executive of Amarin since November 2009 and has contributed substantial executive leadership and operational value to the company. Expanding John's role to CEO was the natural decision as the company embarks on the next stages of its commercial growth," said Ekman. "On behalf of Amarin's employees and Board of Directors, I thank Joe Zakrzewski for the commitment, dedication and leadership he has provided since joining Amarin. We are pleased to have Joe continue as a member of the Board of Directors as we move forward." "Amarin has a well differentiated product and a talented group of experienced professionals with significant records of achievement in the industry. I look forward to increasing our market presence with the current indication for Vascepa while continuing to aggressively pursue additional pathways for market expansion of our flagship product," stated Mr. Thero.